

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

204553Orig1s000

OTHER ACTION LETTERS



NDA 204553

TENTATIVE APPROVAL

KVK-TECH, INC
On behalf of Gator Pharmaceuticals, Inc.
Attention: Ashvin Panchal
Manager – Quality Assurance
110 Terry Drive, Suite 200
Newton, PA 18940

Dear Mr. Panchal,

Please refer to your New Drug Application (NDA) dated November 30, 2012, received December 4, 2012, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for sodium sulfate, potassium sulfate, magnesium sulfate, powder for oral solution, 17.5g/3.13g/1.6g

We acknowledge receipt of your amendments dated March 7, 2013; April 1 & 18, 2013; May 24 & 29, 2013; June 14, 19 & 28 (2), 2013; July 23, 2013 (2); and September 5, 6 & 18 (2), & 30, 2013.

This NDA provides for the use of sodium sulfate, potassium sulfate, magnesium sulfate, powder for oral solution for cleansing of the colon in preparation for colonoscopy in adults.

We have completed our review of this application, as amended. It is tentatively approved under 21 CFR 314.105 for use as recommended in the submitted labeling (text for the package insert, text for the patient instructions for use, medication guide, and carton labels submitted September 30, 2013; and immediate container label submitted September 18, 2013) with the minor editorial revisions listed below.

1. For the Package Insert, Section 2 Dosage and Administration, replace

(b) (4)

(b) (4)

2. For the Package Insert, Subsection 8.5 Geriatric use, in the second and third sentences, replace “TRADENAME”

(b) (4)

3.

(b) (4)

4. For the medication guide, in the **What is the most important information I should know?** section, revise “NSAIDS” to “NSAIDs”.
5. For the instructions for use to be presented in the booklet, add the following after the section **On the day before your colonoscopy** and before **Do not eat or drink anything 2 hours before your colonoscopy**:

Drink only clear liquids:

- after eating a light breakfast the day before your colonoscopy
 - while taking TRADENAME
 - after taking TRADENAME and until 2 hours before your colonoscopy
6. For the instructions for use to be presented in the booklet, in the instructions for Dose 1, add the word “your” so the sentence reads, “Dose 1: Take this dose early in the evening before your colonoscopy, about 10 to 12 hours before you take Dose 2, or when your doctor tells you to take it.”
7. For the instructions for use on the side panel of the carton labeling, delete the fourth bullet and add the following section (before the section **You may eat or drink any of the following clear liquids**):

Drink only clear liquids:

- after eating a light breakfast the day before your colonoscopy
- while taking TRADENAME
- after taking TRADENAME and until 2 hours before your colonoscopy

This determination is based upon information available to the Agency at this time, [i.e., information in your application and the status of current good manufacturing practices (cGMPs) of the facilities used in the manufacture and testing of the drug product]. This determination is subject to change on the basis of any new information that may come to our attention.

The listed drug upon which your application relies is subject to a period of patent protection and therefore final approval of your application under section 505(c)(3) of the Act [21 U.S.C. 355(c)(3)] may not be made effective until the period has expired.

Your application contains certifications to each of the patents under section 505(b)(2)(A)(iv) of the Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of, this drug product under this application (“Paragraph IV certifications”).

Section 505(c)(3)(C) of the Act provides that approval of a new drug application submitted pursuant to section 505(b)(2) of the Act shall be made effective immediately, unless an action is brought for infringement of one or more of the patents that were the subject of the paragraph IV certifications. This action must be taken prior to the expiration of forty-five days from the date the notice provided under section 505(b)(3) is received by the patent owner/approved application holder. You notified us that you complied with the requirements of section 505(b)(3) of the Act.

In addition, you have notified the Agency that the patent owner and/or approved application holder has initiated a patent infringement suit against you with respect to patent 6946149 in the Court of Eastern District of Pennsylvania. Therefore, final approval cannot be granted until:

1. a. expiration of the 30-month period provided for in Section 505(c)(3)(C) beginning on the date of receipt of the 45-day notice required under Section 505(b)(3), unless the court has extended or reduced the period because of the failure of either party to reasonably cooperate in expediting the action, or
- b. the date the court decides that the patent is invalid or not infringed as described in section 505(c)(3)(C)(i), (ii), (iii), or (iv) of the Act, or,
- c. the listed patent has expired, and
2. we are assured there is no new information that would affect whether final approval should be granted.

To obtain final approval of this application, submit an amendment two or six months prior to the: 1.) expiration of the patent or 2.) date you believe that your NDA will be eligible for final approval, as appropriate. In your cover letter, clearly identify your amendment as **“REQUEST FOR FINAL APPROVAL”**. This amendment should provide the legal/regulatory basis for your request for final approval and should include a copy of any relevant court order or judgment settlement, or licensing agreement, as appropriate. In addition to a safety update, the amendment should also identify changes, if any, in the conditions under which your product was tentatively approved, i.e., updated labeling; chemistry, manufacturing, and controls data; and risk evaluation and mitigation strategy (REMS). If there are no changes, clearly state so in your cover letter. Any changes require our review before final approval and the goal date for our review will be set accordingly.

Until we issue a final approval letter, this NDA is not deemed approved.

Please note that this drug product may not be marketed in the United States without final agency approval under Section 505 of the Act. The introduction or delivery for introduction into interstate commerce of this drug product before the final approval date is prohibited under Section 501 of the Act and 21 U.S.C. 331(d).

PROPRIETARY NAME

If you intend to have a proprietary name for this product, the name and its use in the labels must conform to the specifications under 21 CFR 201.10 and 201.15. We recommend that you submit a request for a proposed proprietary name review. See the guidance for industry titled, “Contents of a Complete Submission for the Evaluation of Proprietary Names”, at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/u>

[cm075068.pdf](#) and “PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2008 through 2012”.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We note that if this application is ultimately approved, you will need to meet these requirements.

POSTMARKETING REQUIREMENTS UNDER 505(o)

Section 505(o) of the FDCA authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute (section 505(o)(3)(A)).

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to identify unexpected serious risks of dangerous fluid and electrolyte disturbances with the potential for cardiac sequelae or renal injury, when available data for other drugs in the same pharmacologic class indicate the potential for a serious risk.

Furthermore, the new pharmacovigilance system that FDA is required to establish under section 505(k)(3) of the FDCA has not yet been established and is not sufficient to assess these serious risks.

Finally, we have determined that only clinical trials (rather than a nonclinical or observational study) will be sufficient to identify unexpected serious risks of dangerous fluid and electrolyte disturbances or renal injury, when available data for other drugs in the same pharmacologic class indicate the potential for a serious risk.

Therefore, based on appropriate scientific data, FDA has determined that if this application is ultimately approved, you will be required to conduct the following:

- 1:** A randomized, active control, single-blind trial to evaluate renal and metabolic toxicity and sulfate levels in patients, including elderly patients, patients with renal impairment, and patients with hepatic impairment taking sodium sulfate, potassium sulfate, magnesium sulfate, powder for oral solution prior to colonoscopy.
- 2:** A clinical trial to assess ECG changes to capture maximum effects of sulfate exposures in subjects taking sodium sulfate, potassium sulfate, magnesium sulfate, powder for oral solution.

If this application is ultimately approved, submit the protocols to your IND 113084, with a cross-reference letter to this NDA. Submit all final reports to your NDA. Prominently identify the

submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate:

- **REQUIRED POSTMARKETING PROTOCOL UNDER 505(o)**
- **REQUIRED POSTMARKETING FINAL REPORT UNDER 505(o)**
- **REQUIRED POSTMARKETING CORRESPONDENCE UNDER 505(o)**

If you have any questions, call Matthew Scherer, Regulatory Project Manager, at (301) 796-2307.

Sincerely,

{See appended electronic signature page}

Donna Griebel, MD
Director
Division of Gastroenterology and Inborn Errors
Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling
Carton and Container Labeling

20 Page(s) of Draft Labeling have been Withheld in Full
as b4 (CCI/TS) immediately following this page

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DONNA J GRIEBEL
10/04/2013